ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

AMRN Amarin Corp PLC

0,9289
0,0519 (5,92%)
30 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Amarin Corp PLC AMRN NASDAQ Recibo de Depósito
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,0519 5,92% 0,9289 20:59:39
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
0,884 0,8692 0,9289 0,9209 0,877
mais cotações »

Notícias Recentes

Data Hora Fonte Título
24/04/202415:00GLOBEAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA..
22/04/202409:00GLOBEAmarin Announces Results of Annual General Meeting of..
15/04/202409:00GLOBEAmarin to Report First Quarter 2024 Financial Results and..
08/04/202409:00GLOBEAmarin Highlights Key Data Providing Mechanistic Insights..
08/04/202407:30PRNCANew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl)..
06/04/202416:30GLOBENew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent..
03/04/202409:00GLOBEAmarin Provides Update on VAZKEPA® (Icosapent Ethyl)..
25/03/202409:00GLOBEResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent..
29/02/202409:00GLOBEAmarin Reports Fourth Quarter and Full Year 2023 Financial..
15/02/202410:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
22/01/202409:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
10/01/202409:00GLOBEAmarin Provides Preliminary Fourth Quarter 2023 Selected..
11/12/202310:00GLOBEAmarin to Present at the 42nd Annual J.P. Morgan Healthcare..
12/11/202311:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
01/11/202308:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
31/10/202313:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
26/10/202309:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
19/10/202309:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
12/09/202309:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
09/08/202317:05GLOBEAmarin Provides Pricing & Reimbursement Updates for VAZKEPA..
08/08/202308:00GLOBEAmarin And Neopharm Announce Exclusive Commercialization..
07/08/202308:00GLOBEScottish Medicines Consortium Accepts VAZKEPA® (icosapent..
02/08/202308:11GLOBEAmarin Reports Second Quarter 2023 Financial Results
31/07/202309:00GLOBEAmarin and Lotus Pharmaceuticals Announce Exclusive..
26/07/202309:00GLOBELatest Research Evaluating Clinical Benefits of..
25/07/202317:05GLOBEAmarin Receives Positive Recommendation from Spanish Drug..
20/07/202309:00GLOBEAmarin Board of Directors Announces Executive Compensation..
18/07/202317:16GLOBEAmarin Appoints Patrick Holt as President and Chief..
18/07/202317:15GLOBEAmarin Implements Organizational Restructuring to Strengthen..
21/06/202310:00GLOBEAmarin Announces Vascepa® (Icosapent Ethyl) Approved to..
01/06/202317:30GLOBEAmarin to Present at Two Upcoming Investor Conferences
01/06/202307:00GLOBEAmarin Partner EddingPharm Receives Regulatory Approval for..
12/05/202312:00GLOBEAmarin Highlights New Data Providing Potential Mechanistic..
03/05/202308:00GLOBEAmarin Reports First Quarter 2023 Financial Results and..

Seu Histórico Recente

Delayed Upgrade Clock